Myocardial substrate metabolism in the normal and failing heart.
By W. Stanley, F. Recchia, G. Lopaschuk. Physiological Reviews, 2005
2,054 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Electrical and Electronic Engineering, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/5e36f4db00645a2e75fc606f0472b84e50a84d34
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Mitochondrial function as a therapeutic target in heart failure (2016, neutral): “This switch is most apparent in late and end-stage HF 57 , and is 30% more energetically efficient in the failing heart, because more ATP is produced per mole of oxygen during carbohydrate oxidation 62 .”
- Cardiac Metabolism in Heart Failure - Implications beyond ATP production (2013, neutral): “Pyruvate oxidation is catalyzed by the multienzyme complex pyruvate dehydrogenase (PDH), the activity of which is highly regulated by its products (acetyl-CoA, NADH) and by phosphorylation of its E 1 subunit.(30) The carboxylation of pyruvate is a major anaplerotic pathway (see below).”
- Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “The substrate switch noted earlier is hence thought to be more favorable and provides a protective mechanism as ATP generation from glucose requires less oxygen (6 mol oxygen per mol glucose) as compared to FAs (23 mol oxygen per mol palmitic acid) (Stanley et al. 2005).”
- Association between insulin resistance and the development of cardiovascular disease (2018, background): “The levels of circulating FFAs determines largely FFA uptake in the heart [141].”
- Omega-3 polyunsaturated fatty acids and cardiovascular diseases. (2009, background): “(46) have shown that a high-fat diet increases plasma free fatty acid concentration, activating PPAR-alpha in the heart and stimulating expression of key mitochondrial proteins involving fatty acid oxidation.”
- Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study (2007, background): “Exclusion criteria were as follows: (1) age 70 years, (2) known presence of or medical treatment for coronary artery disease, (3) previous myocardial infarction, (4) metallic implants, (5) pregnancy, or (6) claustrophobia.”
- Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. (2010, background): “The pathological state of the lipid-overloaded, insulin-resistant, and failing heart is commonly referred to as diabetic cardiomyopathy (1, 400).”
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis (2016, background): “and functional manifestation (reduced or preserved ejection fraction) (51).”